US0396971071 - Common Stock - Premarket: 2.97 +0.04 (+1.37%)
NASDAQ:ARDX (1/31/2023, 7:18:57 PM)+0.15 (+5.4%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/amc||Earnings (Next)||02-27 2023-02-27|
|Ins Owners||2.64%||Inst Owners||36.24%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Ardelyx, Inc. is a biopharmaceutical company. The company is headquartered in Fremont, California and currently employs 86 full-time employees. The company went IPO on 2014-06-19. The firm focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The firm's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of hyperphosphatemia, a condition of elevated levels of phosphate in the blood, common among patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
34175 Ardenwood Blvd
Fremont CALIFORNIA 94555
CEO: Michael Raab
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Biopharmaceutical firm Ardelyx (ARDX) has filed to offer and sell up to a maximum aggregate offering price of $250M of its common stock, preferred stock, debt securities, warrants,...
Most experts will advise you to steer clear of under the radar penny stocks – and for good reason. However, keep an eye on these.
Seeking Alpha contributors accurately predicted the 2022 bull run of AbbVie (ABBV), Vertex Pharma (VRTX), and Genmab (GMAB), sometimes even against the consensus. Read the full story here.
Ardelyx (ARDX) said a department of the U.S. Food and Drug Administration ((FDA)) granted an appeal to the agency's complete response letter which had rejected the company's...
Here you can normally see the latest stock twits on ARDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.